Sutherland Kester Maciver

Amoebics has developed a novel approach to tackle bacterial infections. Using a new technology, developed at Edinburgh University, Ameobics is producing antibacterial drugs that promise to be effective in the treatment of infections arising from bacteria, including bacteria that are resistant to treatment by antibiotics. The company was established in 1998 to commercialize work carried out in the laboratory of Dr. Sutherland Maciver in the Medical School of Edinburgh University. With a mix of equity and grant funding, the company has progressed its first product to the point of early preclinical testing. Results to date are very encouraging in terms of support for the firm's first product and also demonstrate the overall potential of the new technology to tackle a range of bacterial infections.

Amoebics has developed a novel approach to tackle bacterial infections. Using a new technology, developed at Edinburgh University, Ameobics is producing antibacterial drugs that promise to be effective in the treatment of infections arising from bacteria, including bacteria that are resistant to treatment by antibiotics. The company was established in 1998 to commercialize work carried out in the laboratory of Dr. Sutherland Maciver in the Medical School of Edinburgh University. With a mix of equity and grant funding, the company has progressed its first product to the point of early preclinical testing. Results to date are very encouraging in terms of support for the firm's first product and also demonstrate the overall potential of the new technology to tackle a range of bacterial infections.